tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Oncolytics reports Q2 EPS (C$0.07) vs. (C$0.10) last year

As of June 30, 2025, the company reported C$14.6M in cash and cash equivalents, projecting a cash runway through key milestones and into the first quarter of 2026. “We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,” said Jared Kelly, Chief Executive Officer of Oncolytics (ONCY). “As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1